Biopharmaceutical Challenges: Pulmonary Delivery of Proteins and Peptides

Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development

Volumn , Issue , 2006, Pages 209-242

  Cheng, Kun ^a   Mahato, Ram I ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Barriers to pulmonary absorption; Biopharmaceutical challenges; Biotech drugs; Experimental models; Limitations of aerosol delivery; Peptide absorption; Pharmacodynamics; Pharmacokinetics; Protein absorption; Pulmonary delivery; Pulmonary system; Structure and physiology

Indexed keywords

EID: 78650674623     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527609628.ch9     Document Type: Chapter

References (122)

1. Agu, R.U., M.I. Ugwoke, M. Armand, R. Kinget, and N. Verbeke. 2001. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2 : 198-209.
2. Choi, W.S., G.G. Murthy, D.A. Edwards, R. Langer, and A.M. Klibanov. 2001. Inhalation delivery of proteins from ethanol suspensions. Proc. Natl. Acad. Sci. USA 98 : 11103-11107.
3. Taylor, G., and L. Kellaway. 2001. Pulmonary Drug Delivery. In: A. Hillery, A. Lloyd, and J. Swarbrick (Eds), Drug Delivery and Targeting: For Pharmacists and Pharmaceutical Scientists. Taylor & Francis, London, pp. 270-300.
4. Hussain, A., J.J. Arnold, M.A. Khan, and F. Ahsan. 2004. Absorption enhancers in pulmonary protein delivery. J. Control. Release 94 : 15-24.
5. Gonda, I. 2000. The ascent of pulmonary drug delivery. J. Pharm. Sci. 89 : 940-945.
6. Cleland, J.L., A. Daugherty, and R. Mrsny. 2001. Emerging protein delivery methods. Curr. Opin. Biotechnol. 12 : 212-219.
7. Mercer, R.R., M.L. Russell, and J.D. Crapo. 1994. Alveolar septal structure in different species. J. Appl. Physiol. 77 : 1060-1066.
8. Gehr, P., M. Bachofen, and E.R. Weibel. 1978. The normal human lung: ultrastructure and morphometric estimation of diffusion capacity. Respir. Physiol. 32 : 121-140.
9. Breeze, R.G., and E.B. Wheeldon. 1977. The cells of the pulmonary airways. Am. Rev. Respir. Dis. 116 : 705-777.
10. Mercer, R.R., M.L. Russell, V.L. Roggli, and J.D. Crapo. 1994. Cell number and distribution in human and rat airways. Am. J. Respir. Cell. Mol. Biol. 10: 613-624.
11. Clarke, S., and D. Pavia. 1984. Aerosols and the Lung: Clinical and Experimental Aspects. Butterworths, London.
12. Kim, K.J., and A.B. Malik. 2003. Protein transport across the lung epithelial barrier. Am. J. Physiol. Lung Cell. Mol. Physiol. 284:L247-L259.
13. McElroy, M.C., and M. Kasper. 2004. The use of alveolar epithelial type I cell-selective markers to investigate lung injury and repair. Eur. Respir. J. 24 : 664-673.
14. Groneberg, D.A., C. Witt, U. Wagner, K.F. Chung, and A. Fischer. 2003. Fundamentals of pulmonary drug delivery. Respir. Med. 97 : 382-387.
15. Cunningham, A.C., D.S. Milne, J. Wilkes, J.H. Dark, T.D. Tetley, and J.A. Kirby. 1994. Constitutive expression of MHC and adhesion molecules by alveolar epithelial cells (type II pneumocytes) isolated from human lung and comparison with immunocytochemical findings. J. Cell Sci. 107 (Pt 2):443-449.
16. Crouch, E., and J.R. Wright. 2001. Surfactant proteins a and d and pulmonary host defense. Annu. Rev. Physiol 63 : 521-554.
17. McCormack, F.X., and J.A. Whitsett. 2002. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J. Clin. Invest. 109 : 707-712.
18. Sayani, A.P., and Y.W. Chien. 1996. Systemic delivery of peptides and proteins across absorptive mucosae. Crit. Rev. Ther. Drug Carrier Syst. 13 : 85-184.
19. Lombry, C., D.A. Edwards, V. Preat, and R. Vanbever. 2004. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am. J. Physiol. Lung Cell. Mol. Physiol. 286:L1002-L1008.
20. Colthorpe, P., S.J. Farr, I.J. Smith, D. Wyatt, and G. Taylor. 1995. The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. Pharm. Res. 12 : 356-359.
21. Niven, R.W., K.L. Whitcomb, L. Shaner, A.Y. Ip, and O.B. Kinstler. 1995. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm. Res. 12 : 1343-1349.
22. Sciarra, J.J., and C.J. Sciarra. 2000. Aerosols. In: Gennaro, A.R. (Ed.), Remington: The Science and Practice of Pharmacy. Lippincott Williams & Wilkins, Baltimore, pp. 963-979.
23. Labiris, N.R., and M.B. Dolovich. 2003. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56 : 588-599.
24. Suarez, S., and A.J. Hickey. 2000. Drug properties affecting aerosol behavior. Respir. Care 45 : 652-666.
25. Newman, S.P., J.E. Agnew, D. Pavia, and S.W. Clarke. 1982. Inhaled aerosols: lung deposition and clinical applications. Clin. Phys. Physiol. Meas. 3 : 1-20.
26. Dolovich, M.B., R.C. Ahrens, D.R. Hess, P. Anderson, R. Dhand, J.L. Rau, G.C. Smaldone, and G. Guyatt. 2005. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 127 : 335-371.
27. Green, J.D. 1994. Pharmaco-toxicological expert report Pulmozyme rhDNase Genentech, Inc. Hum. Exp. Toxicol. 13 Suppl 1:S1-S42.
28. Smyth, H. 2005. Propellant-driven metered-dose inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv. 2 : 53-71.
29. Geller, D.E. 2002. New liquid aerosol generation devices: systems that force pressurized liquids through nozzles. Respir. Care 47 : 1392-1404; discussion 1404-1395.
30. Labiris, N.R., and M.B. Dolovich. 2003. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56 : 600-612.
31. Frijlink, H., and A.D. Boer. 2004. Dry powder inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv. 1 : 67-85.
32. Edwards, D.A., J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M.L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer. 1997. Large porous particles for pulmonary drug delivery. Science 276 : 1868-1871.
33. Folkesson, H.G., M.A. Matthay, B.R. Westrom, K.J. Kim, B.W. Karlsson, and R.H. Hastings. 1996. Alveolar epithelial clearance of protein. J. Appl. Physiol. 80 : 1431-1445.
34. Tronde, A., E. Krondahl, H. von Euler-Chelpin, P. Brunmark, U.H. Bengtsson, G. Ekstrom, and H. Lennernas. 2002. High airway-to-blood transport of an opioid tetrapeptide in the isolated rat lung after aerosol delivery. Peptides 23 : 469-478.
35. Gerde, P., P. Ewing, L. Lastbom, A. Ryrfeldt, J. Waher, and G. Liden. 2004. A novel method to aerosolize powder for short inhalation exposures at high concentrations: isolated rat lungs exposed to respirable diesel soot. Inhal. Toxicol. 16 : 45-52.
36. Mathias, N.R., K.J. Kim, and V.H. Lee. 1996. Targeted drug delivery to the respiratory tract: solute permeability of airinterface cultured rabbit tracheal epithelial cell monolayers. J. Drug Target. 4 : 79-86.
37. Shen, B.Q., W.E. Finkbeiner, J.J. Wine, R.J. Mrsny, and J.H. Widdicombe. 1994. Calu-3: a human airway epithelial cell line that shows cAMP-dependent Cl-secretion. Am. J. Physiol. 266: L493-L501.
38. Mason, R.J., and M.C. Williams. 1980. Phospholipid composition and ultrastructure of A549 cells and other cultured pulmonary epithelial cells of presumed type II cell origin. Biochim. Biophys. Acta 617 : 36-50.
39. Matsukawa, Y., V.H. Lee, E.D. Crandall, and K.J. Kim. 1997. Size-dependent dextran transport across rat alveolar epithelial cell monolayers. J. Pharm. Sci. 86 : 305-309.
40. Shen, J., K.J. Elbert, F. Yamashita, C.M. Lehr, K.J. Kim, and V.H. Lee. 1999. Organic cation transport in rabbit alveolar epithelial cell monolayers. Pharm. Res. 16 : 1280-1287.
41. Elbert, K.J., U.F. Schafer, H.J. Schafers, K.J. Kim, V.H. Lee, and C.M. Lehr. 1999. Monolayers of human alveolar epithelial cells in primary culture for pulmonary absorption and transport studies. Pharm. Res. 16 : 601-608.
42. Helliwell, P.A., D. Meredith, C.A. Boyd, J.R. Bronk, N. Lister, and P.D. Bailey. 1994. Tripeptide transport in rat lung. Biochim. Biophys. Acta 1190 : 430-434.
43. Meredith, D., and C.A. Boyd. 1995. Dipeptide transport characteristics of the apical membrane of rat lung type II pneumocytes. Am. J. Physiol. 269:L137-L143.
44. Morimoto, K., H. Yamahara, V.H. Lee, and K.J. Kim. 1993. Dipeptide transport across rat alveolar epithelial cell monolayers. Pharm. Res. 10 : 1668-1674.
45. Byron, P.R., Z. Sun, H. Katayama, and F. Rypacek. 1994. Solute absorption from the airways of the isolated rat lung. IV. Mechanisms of absorption of fluorophore-labeled poly-′,beta-[N(2-hydroxyethyl)-DL-aspartamide]. Pharm. Res. 11: 221-225.
46. Niven, R.W., F. Rypacek, and P.R. Byron. 1990. Solute absorption from the airways of the isolated rat lung. III. Absorption of several peptidase-resistant, synthetic polypeptides: poly-(2-hydroxyethyl)-aspartamides. Pharm. Res. 7 : 990-994.
47. Hoover, J.L., B.D. Rush, K.F. Wilkinson, J.S. Day, P.S. Burton, T.J. Vidmar, and M.J. Ruwart. 1992. Peptides are better absorbed from the lung than the gut in the rat. Pharm. Res. 9 : 1103-1106.
48. Kim, K.J., Y. Matsukawa, H. Yamahara, V.K. Kalra, V.H. Lee, and E.D. Crandall. 2003. Absorption of intact albumin across rat alveolar epithelial cell monolayers. Am. J. Physiol. Lung Cell Mol. Physiol. 284:L458-L465.
49. John, T.A., S.M. Vogel, R.D. Minshall, K. Ridge, C. Tiruppathi, and A.B. Malik. 2001. Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung. J. Physiol. 533 : 547-559.
50. Hastings, R.H., H.G. Folkesson, and M.A. Matthay. 2004. Mechanisms of alveolar protein clearance in the intact lung. Am. J. Physiol. Lung Cell Mol. Physiol. 286:L679-L689.
51. Matsukawa, Y., H. Yamahara, V.H. Lee, E.D. Crandall, and K.J. Kim. 1996. Horseradish peroxidase transport across rat alveolar epithelial cell monolayers. Pharm. Res. 13 : 1331-1335.
52. Deshpande, D., D. Toledo-Velasquez, L.Y. Wang, C.J. Malanga, J.K. Ma, and Y. Rojanasakul. 1994. Receptor-mediated peptide delivery in pulmonary epithelial monolayers. Pharm. Res. 11: 1121-1126.
53. Laube, B.L., G.W. Benedict, and A.S. Dobs. 1998. The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes. Chest 114 : 1734-1739.
54. Laube, B.L. 2001. Treating diabetes with aerosolized insulin. Chest 120 :99S-106S.
55. Cefalu, W.T. 2001. Novel routes of insulin delivery for patients with type 1 or type 2 diabetes. Ann. Med. 33 : 579-586.
56. Cefalu, W.T. 2001. Inhaled insulin: a proof-of-concept study. Ann. Intern. Med. 134 : 795.
57. Morimoto, K., K. Metsugi, H. Katsumata, K. Iwanaga, and M. Kakemi. 2001. Effects of low-viscosity sodium hyaluronate preparation on the pulmonary absorption of rh-insulin in rats. Drug Dev. Ind. Pharm. 27 : 365-371.
58. Chen, X.J., J.B. Zhu, G.J. Wang, M.X. Zhou, F.M. Xin, N. Zhang, C.X. Wang, and Y.N. Xu. 2002. Hypoglycemic efficacy of pulmonary delivered insulin dry powder aerosol in rats. Acta Pharmacol. Sin. 23 : 467-470.
59. Patton, J.S., J.G. Bukar, and M.A. Eldon. 2004. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin. Pharmacokinet. 43 : 781-801.
60. Quattrin, T., A. Belanger, N.J. Bohannon, and S.L. Schwartz. 2004. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27 : 2622-2627.
61. Skyler, J.S., W.T. Cefalu, I.A. Kourides, W.H. Landschulz, C.C. Balagtas, S.L. Cheng, and R.A. Gelfand. 2001. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-ofconcept study. Lancet 357 : 331-335.
62. 2004. Insulin inhalation: NN 1998. Drugs RD 5 : 46-49.
63. Farr, S.J., A. McElduff, L.E. Mather, J. Okikawa, M.E. Ward, I. Gonda, V. Licko, and R.M. Rubsamen. 2000. Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol. Ther. 2 : 185-197.
64. Brunner, G.A., B. Balent, M. Ellmerer, L. Schaupp, A. Siebenhofer, J.H. Jendle, J. Okikawa, and T.R. Pieber. 2001. Doseresponse relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 44 : 305-308.
65. Henry, R.R., S.R. Mudaliar, W.C. Howland, 3rd, N. Chu, D. Kim, B. An, and R.R. Reinhardt. 2003. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care 26 : 764-769.
66. Harsch, I.A., E.G. Hahn, and P.C. Konturek. 2001. Syringe, pen, inhaler - the evolution of insulin therapy. Med. Sci. Monit. 7 : 833-836.
67. Kobayashi, S., S. Kondo, and K. Juni. 1994. Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers. Pharm. Res. 11: 1239-1243.
68. Kobayashi, S., S. Kondo, and K. Juni. 1996. Pulmonary delivery of salmon cal citonin dry powders containing absorption enhancers in rats. Pharm. Res. 13 : 80-83.
69. Deftos, L.J., J.J. Nolan, B.L. Seely, P.L. Clopton, G.J. Cote, C.L. Whitham, L.J. Florek, T.A. Christensen, and M.R. Hill. 1997. Intrapulmonary drug delivery of salmon calcitonin. Calcif. Tissue Int. 61: 345-347.
70. Okada, H., I. Yamazaki, Y. Ogawa, S. Hirai, T. Yashiki, and H. Mima. 1982. Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: absorption by various routes and absorption enhancement. J. Pharm. Sci. 71: 1367-1371.
71. Adjei, A., and J. Garren. 1990. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm. Res. 7 : 565-569.
72. Adjei, A., D. Sundberg, J. Miller, and A. Chun. 1992. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm. Res. 9 : 244-249.
73. Schreier, H., K.J. McNicol, D.B. Bennett, Z. Teitelbaum, and H. Derendorf. 1994. Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. Pharm. Res. 11: 1056-1059.
74. Bennett, D.B., E. Tyson, C.A. Nerenberg, S. Mah, J.S. de Groot, and Z. Teitelbaum. 1994. Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly anesthetized dog. Pharm. Res. 11: 1048-1055.
75. Bajusz, S., V.J. Csernus, T. Janaky, L. Bokser, M. Fekete, and A.V. Schally. 1988. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int. J. Pept. Protein Res. 32 : 425-435.
76. Szende, B., K. Lapis, T.W. Redding, G. Srkalovic, and A.V. Schally. 1989. Growth inhibition of MXTmammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin. Breast Cancer Res. Treat. 14 : 307-314.
77. Lizio, R., T. Klenner, G. Borchard, P. Romeis, A.W. Sarlikiotis, T. Reissmann, and C.M. Lehr. 2000. Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. Eur. J. Pharm. Sci. 9 : 253-258.
78. Lizio, R., T. Klenner, A.W. Sarlikiotis, P. Romeis, D. Marx, T. Nolte, W. Jahn, G. Borchard, and C.M. Lehr. 2001. Systemic delivery of cetrorelix to rats by a new aerosol delivery system. Pharm. Res. 18 : 771-779.
79. Harper, M., C.G. Hatjis, R.G. Appel, and W.E. Austin. 1987. Vasopressin-resistant diabetes insipidus, liver dysfunction, hyperuricemia and decreased renal function. A case report. J. Reprod. Med. 32 : 862-865.
80. van Bree, J.B., S. Tio, A.G. de Boer, M. Danhof, J.C. Verhoef, and D.D. Breimer. 1990. Transport of desglycinamidearginine vasopressin across the bloodbrain barrier in rats as evaluated by the unit impulse response methodology. Pharm. Res. 7 : 293-298.
81. Kelly, J.M., J.M. Abrahams, P.A. Phillips, F.A. Mendelsohn, Z. Grzonka, and C.I. Johnston. 1989. [125I]-[d(CH2)5, Sar7]-AVP: a selective radioligand for V1 vasopressin receptors. J. Recept. Res. 9 : 27-41.
82. Yamahara, H., K. Morimoto, V.H. Lee, and K.J. Kim. 1994. Effects of protease inhibitors on vasopressin transport across rat alveolar epithelial cell monolayers. Pharm. Res. 11: 1617-1622.
83. Folkesson, H.G., B.R. Westrom, M. Dahlback, S. Lundin, and B.W. Karlsson. 1992. Passage of aerosolized BSA and the nona-peptide dDAVP via the respiratory tract in young and adult rats. Exp. Lung Res. 18 : 595-614.
84. Niven, R.W., F.D. Lott, and J.M. Cribbs. 1993. Pulmonary absorption of recombinant methionyl human granulocyte colony stimulating factor (r-huG-CSF) after intratracheal instillation to the hamster. Pharm. Res. 10 : 1604-1610.
85. Niven, R.W., F.D. Lott, A.Y. Ip, and J.M. Cribbs. 1994. Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the rabbit. Pharm. Res. 11: 1101-1109.
86. Machida, M., M. Hayashi, and S. Awazu. 2000. The effects of absorption enhan cers on the pulmonary absorption of recombinant human granulocyte colonystimulating factor (rhG-CSF) in rats. Biol. Pharm. Bull. 23 : 84-86.
87. Giosue, S., M. Casarini, L. Alemanno, G. Galluccio, P. Mattia, G. Pedicelli, L. Rebek, A. Bisetti, and F. Ameglio. 1998. Effects of aerosolized interferon-′ in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 158 : 1156-1162.
88. Giosue, S., M. Casarini, F. Ameglio, P. Zangrilli, M. Palla, A.M. Altieri, and A. Bisetti. 2000. Aerosolized interferon-′ treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur. Cytokine Netw. 11: 99-104.
89. Kinnula, V., K. Cantell, and K. Mattson. 1990. Effect of inhaled natural interferon-′ on diffuse bronchioalveolar carcinoma. Eur. J. Cancer 26 : 740-741.
90. van Zandwijk, N., E. Jassem, R. Dubbelmann, M.C. Braat, and P. Rumke. 1990. Aerosol application of interferon-′ in the treatment of bronchioloalveolar carcinoma. Eur. J. Cancer 26 : 738-740.
91. Barnes, E., G. Webster, S. Whalley, and G. Dusheiko. 1999. Predictors of a favorable response to ′ interferon therapy for hepatitis C. Clin. Liver Dis. 3: 775-791.
92. Martin, P.L., S. Vaidyanathan, J. Lane, M. Rogge, N. Gillette, B. Niggemann, and J. Green. 2002. Safety and systemic absorption of pulmonary delivered human IFN-beta1a in the nonhuman primate: comparison with subcutaneous dosing. J. Interferon Cytokine Res. 22 : 709-717.
93. Halme, M., P. Maasilta, K. Mattson, and K. Cantell. 1994. Pharmacokinetics and toxicity of inhaled human natural interferon-beta in patients with lung cancer. Respiration 61: 105-107.
94. Beck, J.M., H.D. Liggitt, E.N. Brunette, H.J. Fuchs, J.E. Shellito, and R.J. Debs. 1991. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect. Immun. 59 : 3859-3862.
95. An, Z., X. Wang, P. Astoul, T. Danays, A.R. Moossa, and R.M. Hoffman. 1996. Interferon gamma is highly effective against orthotopically-implanted human pleural adenocarcinoma in nude mice. Anticancer Res. 16 : 2545-2551.
96. Jaffe, H.A., R. Buhl, A. Mastrangeli, K.J. Holroyd, C. Saltini, D. Czerski, H.S. Jaffe, S. Kramer, S. Sherwin, and R.G. Crystal. 1991. Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung. J. Clin. Invest. 88: 297-302.
97. Condos, R., F.P. Hull, N.W. Schluger, W.N. Rom, and G.C. Smaldone. 2004. Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis. Chest 125 : 2146-2155.
98. Raju, B., Y. Hoshino, K. Kuwabara, I. Belitskaya, S. Prabhakar, A. Canova, J.A. Gold, R. Condos, R.I. Pine, S. Brown, W.N. Rom, and M.D.Weiden. 2004. Aerosolized gamma interferon (IFN-gamma) induces expression of the genes encoding the IFN-gamma-inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosis. Infect. Immun. 72 : 1275-1283.
99. Halme, M., P. Maasilta, H. Repo, M. Ristola, E. Taskinen, K. Mattson, and K. Cantell. 1995. Inhaled recombinant interferon gamma in patients with lung cancer: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and monocytes. Int. J. Radiat. Oncol. Biol. Phys. 31: 93-101.
100. Kawata, N., Y. Takimoto, H. Hirakata, T. Fuse, D. Hirano, and Y. Yamanaka. 1994. [Clinical trial of inhalant recombinant interferon-gamma in patients with pulmonary metastasis from renal tumor (preliminary report)]. Hinyokika Kiyo 40 : 773-776.
101. Niven, R.W., K.L. Whitcomb, M.Woodward, J. Liu, and C. Jornacion. 1995. Systemic absorption and activity of recombinant consensus interferons after intratracheal instillation and aerosol administration. Pharm. Res. 12 : 1889-1895.
102. Kao, J.H., P.J. Chen, M.Y. Lai, and D.S. Chen. 2000. Efficacy of consensus interferon in the treatment of chronic hepati tis C. J. Gastroenterol. Hepatol. 15 :1418-1423.
103. Ip, A.Y., T. Arakawa, H. Silvers, C.M. Ransone, and R.W. Niven. 1995. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization. J. Pharm. Sci. 84 : 1210-1214.
104. Komada, F., S. Iwakawa, N. Yamamoto, H. Sakakibara, and K. Okumura. 1994. Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J. Pharm. Sci. 83 : 863-867.
105. Knight, K.R., J.G. Burdon, L. Cook, S. Brenton, M. Ayad, and E.D. Janus. 1997. The proteinase-antiproteinase theory of emphysema: a speculative analysis of recent advances into the pathogenesis of emphysema. Respirology 2 : 91-95.
106. Coakley, R.J., C. Taggart, S. O'Neill, and N.G. McElvaney. 2001. Alpha1-antitrypsin deficiency: biological answers to clinical questions. Am. J. Med. Sci. 321: 33-41.
107. Hubbard, R.C., and R.G. Crystal. 1990. Strategies for aerosol therapy of ′ 1-antitrypsin deficiency by the aerosol route. Lung 168 Suppl:565-578.
108. Smith, R.M., L.D. Traber, D.L. Traber, and R.G. Spragg. 1989. Pulmonary deposition and clearance of aerosolized ′-1-proteinase inhibitor administered to dogs and to sheep. J. Clin. Invest. 84 : 1145-1154.
109. Wright, C.D., J.A. Kennedy, R.J. Zitnik, and M.A. Kashem. 1999. Inhibition of murine neutrophil serine proteinases by human and murine secretory leukocyte protease inhibitor. Biochem. Biophys. Res. Commun. 254 : 614-617.
110. Agerberth, B., J. Grunewald, E. Castanos-Velez, B. Olsson, H. Jornvall, H.Wigzell, A. Eklund, and G.H. Gudmundsson. 1999. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am. J. Respir. Crit. Care Med. 160 : 283-290.
111. Gossage, J.R., E.A. Perkett, J.M. Davidson, B.C. Starcher, D. Carmichael, K.L. Brigham, and B. Meyrick. 1995. Secretory leukoprotease inhibitor attenuates lung injury induced by continuous air embolization into sheep. J. Appl. Physiol. 79 : 1163-1172.
112. Vogelmeier, C., R. Buhl, R.F. Hoyt, E. Wilson, G.A. Fells, R.C. Hubbard, H.P. Schnebli, R.C. Thompson, and R.G. Crystal. 1990. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. J. Appl. Physiol. 69 : 1843-1848.
113. Gast, A., W. Anderson, A. Probst, H. Nick, R.C. Thompson, S.P. Eisenberg, and H. Schnebli. 1990. Pharmacokinetics and distribution of recombinant secretory leukocyte proteinase inhibitor in rats. Am. Rev. Respir. Dis. 141:889-894.
114. McElvaney, N.G., H. Nakamura, P. Birrer, C.A. Hebert, W.L. Wong, M. Alphonso, J.B. Baker, M.A. Catalano, and R.G. Crystal. 1992. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J. Clin. Invest. 90 : 1296-1301.
115. Vogelmeier, C., R.C. Hubbard, G.A. Fells, H.P. Schnebli, R.C. Thompson, H. Fritz, and R.G. Crystal. 1991. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J. Clin. Invest. 87 : 482-488.
116. Doring, G. 1999. Serine proteinase inhibitor therapy in ′(1)-antitrypsin inhibitor deficiency and cystic fibrosis. Pediatr. Pulmonol. 28 : 363-375.
117. Morrow, P.E. 1986. Factors determining hygroscopic aerosol deposition in airways. Physiol. Rev. 66 : 330-376.
118. Ferron, G.A. 1994. Aerosol properties and lung deposition. Eur. Respir. J. 7 : 1392-1394.
119. Hillery, A., A. Lloyd, and J. Swarbrick (Eds.) 2001. Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists. Taylor and Francis, London.
120. Hess, D.R. 2000. Nebulizers: principles and performance. Respir. Care 45 : 609-622.
121. Pfutzner, A., A.E. Mann, and S.S. Steiner. 2002. Technosphere/Insulin - a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol. Ther. 4 : 589-594.
122. Cefalu, W.T., J.S. Skyler, I.A. Kourides, W.H. Landschulz, C.C. Balagtas, S. Cheng, and R.A. Gelfand. 2001. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann. Intern. Med. 134 : 203-207.